Healthcare Losers: Inovio Pharmaceuticals Inc (NYSEMKT:INO), Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), Evoke Pharma Inc (NASDAQ:EVOK), Cerulean Pharma Inc (NASDAQ:CERU)

On Friday, Inovio Pharmaceuticals Inc (NYSEMKT:INO) announced that its shareholders had approved 1-for-4 reverse stock split of company common stock. Company shares sank more than 5% in morning trading. The company said that the effective date of the reverse stock split would be disclosed at a future date after The company complies with “standard NYSE administrative processes.” The company stock performance was -9.09% in last session and finished the day at $2.00. Traded volume was 9.95million shares in the last session and the average volume of the stock remained 7.56million shares. The beta of the stock remained 4.11. Inovio Pharmaceuticals Inc (NYSEMKT:INO) insider ownership is 2.50%.

Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) in its Quarterly report on 15 May 2014 revealed that for the three months ended March 31, 2014 we recognized $1,410, in license revenues compared to $2,500 in license revenues recognized during the same period in the prior year. Revenues recognized in 2014 and 2013 are related to a license agreement we entered into with resolution MD, LLC granting resolution MD, LLC rights to our Accudel delivery technology to be used for anti-cellulite formulations. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) dropped -6.07 percent to $5.73 Friday on volume of 12,094.00million shares. The intra-day range of the stock was $5.66 to $6.49. Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) has a market capitalization of $52.17million.

Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, on 13 May 2014 announced its financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, net loss was approximately $3.0 million, or $0.49 per share, compared to a net loss of approximately $494,000, or $0.44 per share, for the three-month period ended March 31, 2013. Research and development expenses totaled approximately $1.9 million for the first quarter of 2014, compared to approximately $111,000 for the first quarter of 2013.Evoke Pharma Inc (NASDAQ:EVOK)’s stock on May 23, 2014 reported a decrease of -5.04% to the closing price of $7.35. Its fifty two weeks range is $6.48 -$14.25. The total market capitalization recorded $44.81million. The overall volume in the last trading session was 19,032.00million shares. In its share capital, ECOK has 6.10million outstanding shares.

Alder is the first company in Washington state to go public this year, and its performance on 08 May 2014 speaked to the rough market facing biotech companies that are looking to go public. The company’s initial share price of $10 was below the expected range of $13 to $15 a share. Cerulean Pharma Inc (NASDAQ:CERU) and Aldeyra Pharmaceuticals, which both had offerings earlier this month, faced similar pricing disappointments. On Friday, shares of Cerulean Pharma Inc (NASDAQ:CERU) dropped -8.64% to close the day at $5.71. Company monthly performance is recorded as -15.28%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone